Editas Medicine EDIT
NASDAQ EDIT
$2.47 -0.04 (-1.64%)
As of: Oct 22, 2026 · 3:38 PM EDT

Editas Medicine (EDIT) Non Operating Interest Expenses (2025)

Updated

Editas Medicine (EDIT) reported Non Operating Interest Expenses of $2.4 million for Q3 2025, up 18.8% from the prior quarter.

Analysis

Editas Medicine (EDIT) Non Operating Interest Expenses (2025) Analysis & Trends

Over the twelve months ended Sep 30, 2025, Editas Medicine's Non Operating Interest Expenses came in at $6.64 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,170.46 Bn 1,139.04 Bn 19.71 Bn -
2 Johnson & Johnson 648.38 Bn 568.24 Bn 17.30 Bn 217.00 Mn
3 AbbVie 504.43 Bn 477.54 Bn 12.70 Bn -
4 Merck 367.73 Bn 322.11 Bn 12.21 Bn -
5 Novartis Ag 303.35 Bn 267.34 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 268.20 Bn 241.88 Bn 12.86 Bn 435.00 Mn
7 Amgen 242.55 Bn 197.95 Bn 7.24 Bn 673.00 Mn
8 Gilead Sciences 194.80 Bn 169.00 Bn 6.22 Bn 247.00 Mn
9 Pfizer 173.31 Bn 119.95 Bn 10.94 Bn -
10 Editas Medicine 221.62 Mn -490.14 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 2.40 Mn
Jun 30, 2025 2.02 Mn
Mar 31, 2025 2.22 Mn
API Access

Editas Medicine Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=EDIT&period=max&api_key=YOUR_API_KEY